Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) — Working Capital to Net Assets Ratio
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) has a Working Capital to Net Assets ratio of 31.7% as of March 2026. Working capital of CN¥791.96 Million (current assets of CN¥1.70 Billion minus current liabilities of CN¥906.46 Million) is measured against net assets of CN¥2.50 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Hangzhou Bio-Sincerity Pharma-Tech Co.Lt (301096) flexibility index to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Working Capital to Net Assets (2019–2025)
This chart shows how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s Working Capital to Net Assets ratio has evolved across 7 annual periods from 2019 to 2025. As of March 2026, the ratio stands at 31.7%, reflecting working capital of CN¥791.96 Million against net assets of CN¥2.50 Billion CNY. See Hangzhou Bio-Sincerity Pharma-Tech Co.Lt (301096) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2025, covering 7 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see Hangzhou Bio-Sincerity Pharma-Tech Co.Lt market cap and net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 25.4% | CN¥632.17 Million | CN¥2.49 Billion | CN¥1.55 Billion | CN¥919.91 Million | ▼ -4.7 pp |
| 2024 | 30.1% | CN¥776.10 Million | CN¥2.58 Billion | CN¥1.55 Billion | CN¥769.38 Million | ▲ +1.7 pp |
| 2023 | 28.4% | CN¥761.59 Million | CN¥2.68 Billion | CN¥1.61 Billion | CN¥846.19 Million | ▼ -24.8 pp |
| 2022 | 53.1% | CN¥1.32 Billion | CN¥2.48 Billion | CN¥1.61 Billion | CN¥290.70 Million | ▼ -22.5 pp |
| 2021 | 75.6% | CN¥1.75 Billion | CN¥2.32 Billion | CN¥2.23 Billion | CN¥472.69 Million | ▲ +41.1 pp |
| 2020 | 34.5% | CN¥117.10 Million | CN¥339.54 Million | CN¥238.79 Million | CN¥121.69 Million | ▼ -22.3 pp |
| 2019 | 56.8% | CN¥158.36 Million | CN¥278.74 Million | CN¥232.66 Million | CN¥74.30 Million | — |